COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021

Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis Jg. 27; H. 6; S. 864
Hauptverfasser:	Achiron, Anat, Dolev, Mark, Menascu, Shay, Zohar, Daniela-Noa, Dreyer-Alster, Sapir, Miron, Shmuel, Shirbint, Emanuel, Magalashvili, David, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Polliack, Michael, Falb, Rina, Gurevich, Michael
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England 01.05.2021
Schlagworte:	COVID-19 Multiple sclerosis adverse events acute relapse immune response vaccination
ISSN:	1477-0970, 1477-0970
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients. We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients. Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs. COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted.
AbstractList	Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed.BACKGROUNDSince vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed.Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients.OBJECTIVECharacterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients.We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients.METHODSWe assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients.Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs.RESULTSBetween 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs.COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted.CONCLUSIONCOVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted. Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be carefully assessed. Characterize safety and occurrence of immediate relapses following COVID-19 vaccination in a large cohort of MS patients. We assessed the safety of BNT162b2 COVID-19 vaccination in adult MS patients. Between 20 December 2020 and 25 January 2021, 555 MS patients received the first dose of BNT162b2 vaccine and 435 received the second dose. There were three cases of COVID-19 infection encountered after the first dose. Safety profile of COVID-19 vaccine was characterized by pain at the injection site, fatigue, and headache. No increased risk of relapse activity was noted over a median follow-up of 20 and 38 days after first and second vaccine doses, respectively. The rate of patients with acute relapse was 2.1% and 1.6% following the first and second doses, respectively, similar to the rate in non-vaccinating patients during the corresponding period. Mild increase in the rate of adverse events was noted in younger patients (18-55 years), among patients with lower disability (Expanded Disability Status Scale (EDSS) ⩽3.0), and in patients treated with immunomodulatory drugs. COVID-19 BNT162b2 vaccine proved safe for MS patients. No increased risk of relapse activity was noted.
Author	Stern, Yael Achiron, Anat Shirbint, Emanuel Flechter, Shlomo Gurevich, Michael Zohar, Daniela-Noa Miron, Shmuel Falb, Rina Guber, Diana Polliack, Michael Menascu, Shay Dolev, Mark Magalashvili, David Givon, Uri Dreyer-Alster, Sapir
Author_xml	– sequence: 1 givenname: Anat orcidid: 0000-0002-2020-3126 surname: Achiron fullname: Achiron, Anat organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 2 givenname: Mark surname: Dolev fullname: Dolev, Mark organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 3 givenname: Shay surname: Menascu fullname: Menascu, Shay organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 4 givenname: Daniela-Noa surname: Zohar fullname: Zohar, Daniela-Noa organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 5 givenname: Sapir surname: Dreyer-Alster fullname: Dreyer-Alster, Sapir organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 6 givenname: Shmuel surname: Miron fullname: Miron, Shmuel organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 7 givenname: Emanuel surname: Shirbint fullname: Shirbint, Emanuel organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 8 givenname: David surname: Magalashvili fullname: Magalashvili, David organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 9 givenname: Shlomo surname: Flechter fullname: Flechter, Shlomo organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 10 givenname: Uri surname: Givon fullname: Givon, Uri organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 11 givenname: Diana surname: Guber fullname: Guber, Diana organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 12 givenname: Yael surname: Stern fullname: Stern, Yael organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 13 givenname: Michael surname: Polliack fullname: Polliack, Michael organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 14 givenname: Rina surname: Falb fullname: Falb, Rina organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel – sequence: 15 givenname: Michael surname: Gurevich fullname: Gurevich, Michael organization: Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gann, Israel/Laura Schwarz-Kipp Chair of Research of Autoimmune Diseases, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33856242$$D View this record in MEDLINE/PubMed
BookMark	eNpNkEtLAzEYRYNUbK3-ADeSpZvRvDNxJ9VqodCNj51DJv2GRmYy4yTT0n9vwQqu7lkcLpd7jkahDYDQFSW3lGp9R7lkQuaSUUoIF1qdoAkVWmfEaDL6x2N0HuMXIURrLs_QmPNcKibYBH3OVu-Lx4wavLXO-WCTbwP2AXcHgpAi3vm0wc1QJ9_VgKOroW-jj_f4Y2MT3gHe2C3gGmwfEi73eA5lP9h-jxlh9AKdVraOcHnMKXqbP73OXrLl6nkxe1hmTiiVMsOhdNJpUVlNwDojLF8bwUtq8rUpiVXCaMeooZVzOQhVWSgtc4qDyYETNkU3v71d334PEFPR-Oigrm2AdogFk5QzIRQVB_X6qA5lA-ui631zmFv8fcJ-AGwcZJU
CitedBy_id	crossref_primary_10_1212_NXI_0000000000001104 crossref_primary_10_3390_life12091338 crossref_primary_10_1016_j_heliyon_2023_e23944 crossref_primary_10_1016_j_msard_2021_103363 crossref_primary_10_1016_j_msard_2022_104175 crossref_primary_10_1016_j_msard_2022_103486 crossref_primary_10_3390_neurolint13040066 crossref_primary_10_3389_fimmu_2021_781843 crossref_primary_10_1007_s00415_022_11237_1 crossref_primary_10_1177_20552173211061543 crossref_primary_10_3389_fonc_2022_855723 crossref_primary_10_1007_s00415_022_11003_3 crossref_primary_10_1038_s41582_022_00646_5 crossref_primary_10_1186_s40001_024_01639_4 crossref_primary_10_1007_s10072_022_05966_4 crossref_primary_10_1016_j_ncl_2023_06_006 crossref_primary_10_1016_j_jneuroim_2021_577785 crossref_primary_10_7759_cureus_32799 crossref_primary_10_1007_s40120_023_00520_6 crossref_primary_10_1016_j_msard_2022_104172 crossref_primary_10_3389_fneur_2023_1097799 crossref_primary_10_1002_rmv_2309 crossref_primary_10_3389_fimmu_2022_868915 crossref_primary_10_1016_j_jns_2023_122852 crossref_primary_10_1016_j_msard_2022_104167 crossref_primary_10_1016_j_vaccine_2021_09_030 crossref_primary_10_1016_j_jns_2021_120034 crossref_primary_10_1016_j_msard_2023_104865 crossref_primary_10_3390_brainsci12030407 crossref_primary_10_1136_jnnp_2021_327200 crossref_primary_10_1016_j_nerep_2021_100006 crossref_primary_10_1016_j_msard_2021_103415 crossref_primary_10_1111_ene_15028 crossref_primary_10_3390_vaccines10111896 crossref_primary_10_1016_j_jns_2021_120030 crossref_primary_10_1186_s10194_022_01400_4 crossref_primary_10_3390_jcm14082665 crossref_primary_10_3389_fneur_2021_721502 crossref_primary_10_1016_j_msard_2024_106221 crossref_primary_10_1016_j_msard_2023_104582 crossref_primary_10_1177_20552173221085242 crossref_primary_10_25259_JNRP_496_2023 crossref_primary_10_1007_s11910_022_01211_9 crossref_primary_10_3389_fimmu_2024_1431403 crossref_primary_10_1007_s00415_021_10647_x crossref_primary_10_1016_j_msard_2021_103382 crossref_primary_10_3389_fimmu_2022_946356 crossref_primary_10_1016_j_msard_2022_104033 crossref_primary_10_1016_j_msard_2021_103142 crossref_primary_10_4274_tnd_2022_97493 crossref_primary_10_1016_j_msard_2022_103863 crossref_primary_10_1016_j_jneuroim_2025_578694 crossref_primary_10_1016_j_clinsp_2022_100142 crossref_primary_10_1016_j_msard_2021_103028 crossref_primary_10_3390_vaccines11061114 crossref_primary_10_1007_s00739_021_00761_w crossref_primary_10_1111_ene_15830 crossref_primary_10_1177_17562864211058298 crossref_primary_10_3390_vaccines10050763 crossref_primary_10_1097_01_NT_0000756476_10524_9d crossref_primary_10_1016_j_clineuro_2022_107374 crossref_primary_10_1016_j_vaccine_2023_09_002 crossref_primary_10_1177_13524585231197928 crossref_primary_10_3390_vaccines9101140 crossref_primary_10_1007_s00415_025_13188_9 crossref_primary_10_7759_cureus_21374 crossref_primary_10_1212_NXI_0000000000200163 crossref_primary_10_1186_s12883_025_04095_7 crossref_primary_10_3390_biomedicines10123034 crossref_primary_10_1016_j_jneuroim_2021_577765 crossref_primary_10_1016_j_ebiom_2021_103581 crossref_primary_10_1080_1744666X_2022_2064845 crossref_primary_10_1177_13524585231179669 crossref_primary_10_1016_j_msard_2022_104022 crossref_primary_10_3390_jcm11226855 crossref_primary_10_3389_fneur_2021_765954 crossref_primary_10_1016_j_msard_2021_103433 crossref_primary_10_1177_20552173211057110 crossref_primary_10_1111_all_15406 crossref_primary_10_1007_s15005_021_2009_2 crossref_primary_10_3390_ijms24119231 crossref_primary_10_3390_vaccines9070773 crossref_primary_10_1007_s13311_021_01165_9 crossref_primary_10_3390_vaccines11121859 crossref_primary_10_3389_fimmu_2023_1106472 crossref_primary_10_3389_fneur_2022_913283 crossref_primary_10_1055_s_0043_1767725 crossref_primary_10_1177_13524585231154780 crossref_primary_10_1016_j_msard_2022_104141 crossref_primary_10_1016_j_msard_2022_103690 crossref_primary_10_3389_fgwh_2021_761511 crossref_primary_10_1007_s10072_022_06287_2 crossref_primary_10_1007_s00415_021_10648_w crossref_primary_10_1007_s10072_023_07282_x crossref_primary_10_1016_j_ebiom_2022_104411 crossref_primary_10_1007_s15005_021_2149_4 crossref_primary_10_1016_j_msard_2021_103321 crossref_primary_10_7759_cureus_36323 crossref_primary_10_1016_j_jiph_2021_05_020 crossref_primary_10_1016_j_msard_2022_104014 crossref_primary_10_1007_s10072_024_07578_6 crossref_primary_10_1007_s00415_021_10663_x crossref_primary_10_1007_s40120_021_00288_7 crossref_primary_10_1016_j_vaccine_2025_127342 crossref_primary_10_1212_CPJ_0000000000001164 crossref_primary_10_7759_cureus_75889 crossref_primary_10_1016_j_msard_2022_104371 crossref_primary_10_1159_000529982 crossref_primary_10_1016_j_jneuroim_2021_577627 crossref_primary_10_1016_j_bbih_2024_100788 crossref_primary_10_1016_j_msard_2022_104120 crossref_primary_10_1016_j_msard_2021_103455 crossref_primary_10_1111_ene_15989 crossref_primary_10_1177_17562864211070684 crossref_primary_10_1016_j_msard_2022_103712 crossref_primary_10_1177_13524585231185249 crossref_primary_10_3389_fneur_2022_828616 crossref_primary_10_1016_j_msard_2023_104707 crossref_primary_10_3389_fimmu_2022_1045101 crossref_primary_10_4103_0028_3886_359233 crossref_primary_10_1111_ene_16163 crossref_primary_10_1007_s00415_023_12034_0 crossref_primary_10_1016_j_msard_2022_103708 crossref_primary_10_1097_WCO_0000000000001066 crossref_primary_10_1136_jnnp_2022_329123 crossref_primary_10_1016_j_vaccine_2024_06_028 crossref_primary_10_1007_s00415_023_11935_4 crossref_primary_10_1016_j_jneuroim_2021_577755 crossref_primary_10_3390_v15071569 crossref_primary_10_1038_s41598_023_41271_6 crossref_primary_10_3390_biom11091372 crossref_primary_10_3390_jcm12175460 crossref_primary_10_4103_1673_5374_346539 crossref_primary_10_3389_fimmu_2021_755333 crossref_primary_10_1002_acn3_51688 crossref_primary_10_1016_j_jocn_2022_08_012 crossref_primary_10_1016_j_msard_2021_103343 crossref_primary_10_1016_j_neurol_2022_11_003 crossref_primary_10_3389_fimmu_2021_701752 crossref_primary_10_1186_s13584_022_00548_3 crossref_primary_10_1007_s10072_023_06609_y crossref_primary_10_1016_j_neurot_2023_e00307 crossref_primary_10_1007_s40120_023_00448_x crossref_primary_10_1177_17562864211022581 crossref_primary_10_1007_s13760_021_01775_2 crossref_primary_10_1016_j_jneuroim_2021_577686 crossref_primary_10_1080_21645515_2022_2041945 crossref_primary_10_2500_aap_2023_44_230049 crossref_primary_10_1007_s00415_021_10780_7 crossref_primary_10_3389_fneur_2022_1018785 crossref_primary_10_1177_20552173231191170 crossref_primary_10_1016_j_msard_2022_104104 crossref_primary_10_1016_j_jneuroim_2021_577696 crossref_primary_10_1016_j_lanepe_2024_100979 crossref_primary_10_1038_s41598_024_62541_x crossref_primary_10_3390_vaccines11091456 crossref_primary_10_1016_S2665_9913_21_00181_8 crossref_primary_10_1111_ene_15368 crossref_primary_10_3390_jcm12113640 crossref_primary_10_1212_WNL_0000000000012578 crossref_primary_10_1177_13524585221109397 crossref_primary_10_3389_fimmu_2023_1004795 crossref_primary_10_3390_neurolint14020030 crossref_primary_10_3389_fneur_2022_796882 crossref_primary_10_1038_s41467_024_47013_0 crossref_primary_10_3390_ctn7010002 crossref_primary_10_3390_vaccines10040596 crossref_primary_10_1007_s00115_021_01155_4 crossref_primary_10_3389_fneur_2023_1092999 crossref_primary_10_1016_j_jaim_2023_100737 crossref_primary_10_1002_hsr2_70119 crossref_primary_10_1177_13524585221150881
ContentType	Journal Article
DBID	NPM 7X8
DOI	10.1177/13524585211003476
DatabaseName	PubMed MEDLINE - Academic
DatabaseTitle	PubMed MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic PubMed
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1477-0970
ExternalDocumentID	33856242
Genre	Journal Article
GroupedDBID	--- -TM .2E .2F .2G .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31S 31U 31X 31Y 31Z 36B 39C 4.4 53G 54M 5VS 7X7 88E 8FI 8FJ 8R4 8R5 AABMB AABOD AACKU AACMV AACTG AADUE AAEWN AAGGD AAGMC AAJIQ AAJOX AAJPV AAKGS AANSI AAPEO AAQDB AAQXH AAQXI AARDL AARIX AATAA AATBZ AAUAS AAXOT AAYTG AAZBJ ABAFQ ABAWC ABAWP ABCCA ABCJG ABDWY ABEIX ABFWQ ABHFT ABHKI ABHQH ABJIS ABJNI ABKRH ABLUO ABNCE ABPGX ABPNF ABQKF ABQXT ABRHV ABUJY ABUWG ABVFX ABVVC ABYTW ACARO ACDSZ ACDXX ACFEJ ACFMA ACFYK ACGBL ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLHI ACLZU ACNXM ACOFE ACOXC ACPRK ACROE ACRPL ACSIQ ACUAV ACUIR ACXKE ACXMB ADBBV ADDLC ADEIA ADMPF ADNBR ADNMO ADNON ADRRZ ADTBJ ADUCT ADUKL ADVBO ADYCS ADZYD ADZZY AECGH AECVZ AEDTQ AEKYL AENEX AEPTA AEQLS AERKM AESZF AEUHG AEWDL AEWHI AEXFG AEXNY AFEET AFKBI AFKRA AFKRG AFMOU AFQAA AFUIA AFVCE AFWMB AGHKR AGKLV AGNHF AGPXR AGWFA AGWNL AHDMH AHHFK AHMBA AIGRN AJABX AJEFB AJMMQ AJSCY AJUZI AJXAJ AJXGE ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV ASPBG AUTPY AVWKF AYAKG AZFZN AZQEC B3H B8M B8O B8R B8Z B93 B94 BBRGL BDDNI BENPR BKIIM BKNYI BKSCU BPACV BPHCQ BSEHC BVXVI BWJAD BYIEH CAG CBRKF CCPQU CDWPY CFDXU COF CORYS CQQTX CS3 CUTAK DB0 DC- DC0 DD- DD0 DE- DF0 DO- DOPDO DU5 DV7 DV9 D~Y EBS EJD EMOBN F5P FD6 FEDTE FHBDP FYUFA GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HMCUK HVGLF HZ~ J8X K.F K.J K9- M0R M1P M4V N9A NPM O9- P.B P2P PHGZT PQQKQ PROAC PSQYO Q1R Q2X Q7K Q7L Q7R Q7U Q7X Q82 Q83 ROL S01 SAUOL SCNPE SDB SFB SFC SFK SFN SFT SGA SGO SGP SGR SGV SGX SGZ SHG SNB SPJ SPQ SPV SQCSI STM UKHRP XJT ZONMY ZPPRI ZRKOI ZSSAH 7X8 AAPII ABIDT ABJZC ADEBD AJGYC AJHME AJVBE SASJQ
ID	FETCH-LOGICAL-c466t-93ebc5c74fa70eac94a3d943b198d9b0a6497c2191fcc8e46faeba2c63e98e302
IEDL.DBID	7X8
ISICitedReferencesCount	176
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000648631300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1477-0970
IngestDate	Thu Oct 02 10:53:58 EDT 2025 Thu Apr 03 07:07:21 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	COVID-19 Multiple sclerosis adverse events acute relapse immune response vaccination
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c466t-93ebc5c74fa70eac94a3d943b198d9b0a6497c2191fcc8e46faeba2c63e98e302
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0002-2020-3126
OpenAccessLink	https://pubmed.ncbi.nlm.nih.gov/PMC8114441
PMID	33856242
PQID	2513244614
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2513244614 pubmed_primary_33856242
PublicationCentury	2000
PublicationDate	2021-05-01
PublicationDateYYYYMMDD	2021-05-01
PublicationDate_xml	– month: 05 year: 2021 text: 2021-05-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Multiple sclerosis
PublicationTitleAlternate	Mult Scler
PublicationYear	2021
SSID	ssj0007735
Score	2.6541727
Snippet	Since vaccination against coronavirus disease 2019 (COVID-19) became available, risks related to vaccinating patients with multiple sclerosis (MS) need to be...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	864
Title	COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021
URI	https://www.ncbi.nlm.nih.gov/pubmed/33856242 https://www.proquest.com/docview/2513244614
Volume	27
WOSCitedRecordID	wos000648631300010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_TG_iOA12CZp0ngRUYeCmzvo2MmSJinu0k07J_vvfekHOwmClx4KKenr6_u9r_weQhfGcuEyG5HA6IDwiEqSUh0Tw7hkwmrLylP8gyfZ68XDoerXCbeibqtsbGJpqO3Y-Bz5JeAwYD8HNLmefBA_NcpXV-sRGsuoxcCV8Vothwu2cCnLAZshl5IESjZVTU-4FILjwcFV9vFPAPsSv3uYJdJ0Nv-7xy20UfuY-KZSim205PIdtNatq-i76O32efB4R0KFZ9rArfLj4FGOa5LVAvvsLG56DXEBTwEwHRVX2DN942-H3_XM4XLixBSnc9yByBp0bY4pgPkeeu3cv9w-kHrOAjFciClRzKUmMpJnWgZgiBXXzCrO0lDFVqWBFlxJA6YtzIyJHReZdqmmRjCnYscCuo9W8nHuDhEWghsQq_UsONzA-jDzpdiQWhoZR8M2Om8kl4Ae--KEzt34q0gWsmujg0r8yaQi3EggjI78OZajP6w-Ruv-VauexBPUyuAvdqdo1cymo-LzrFQQuPb63R--aMK6
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+vaccination+in+patients+with+multiple+sclerosis%3A+What+we+have+learnt+by+February+2021&rft.jtitle=Multiple+sclerosis&rft.au=Achiron%2C+Anat&rft.au=Dolev%2C+Mark&rft.au=Menascu%2C+Shay&rft.au=Zohar%2C+Daniela-Noa&rft.date=2021-05-01&rft.eissn=1477-0970&rft.volume=27&rft.issue=6&rft.spage=864&rft_id=info:doi/10.1177%2F13524585211003476&rft_id=info%3Apmid%2F33856242&rft_id=info%3Apmid%2F33856242&rft.externalDocID=33856242
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon